Veritas begins preparation for cannabis clinical trial 2017-01-31 17:19 ET - News Release
Dr. Lui Franciosi reports
VERITAS-CANNEVERT COMMENCES PREPARATION OF FIRST CLINICAL TRIALS OF CANNABIS TARGETING PAIN
Veritas Pharma Inc. is working with its research arm, Cannevert Therapeutics Ltd., to design and implement the first clinical trials of cannabis strains targeting pain. Leading contract research organizations (CROs) with clinical experience of evaluating cannabis and pain are being considered for cost estimates and timelines.
Veritas chief executive officer Dr. Lui Franciosi stated, "Cannevert's chemical and animal studies have identified suitable strains that warrant immediate human trials, which will be done to the highest standards at institutes of high repute."
Veritas and Cannevert intend to implement these clinical trials this year that meets the highest quality standards, such as good clinical practices (GCPs). CROs with experience in evaluating cannabis for the treatment of pain are currently being visited and screened for suitability. Once a site is identified and a contract negotiated, a formal announcement will be made.